Opus Genetics completes enrollment in phase 3 eye gene therapy trial

August 3, 2026 7:00 AM

Opus Genetics, Inc. (Nasdaq: IRD) announced it has completed patient enrollment in its registrational Phase 3 clinical trial evaluating OPGx-LCA5 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found